|
|
FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc.
508-359-4005, x108
Pico-Tesla’s Magneceutical® Therapy
featured in this month’s EP Lab Digest
In vivo study at Univ. of Oklahoma Health Sciences Center
suggests low-level electromagnetic fields (EMFs)
can prevent and reverse involuntary remodeling
of the heart caused by atrial fibrillation (A-Fib)
“Use of electromagnetic fields can suppress atrial fibrillation.”
Benjamin J. Scherlag, Ph.D., professor of medicine, Heart Rhythm
Institute, Univ. of Oklahoma Health Sciences Center
LITTLETON, Colo., Aug. 10, 2010 —Emerging medical technology company Pico-Tesla, The
Magneceutical® Company, announced today that its Magneceutical® Therapy and Resonator™
devi ce are featured in this month’s issue of EP Lab Digest. The article — “On the Horizon:
Using Low-Level Electromagnetic Fields to Treat Atrial Fibrillation” — was written by Jodie
Elrod, editor of EP Lab Digest.
In May 2010, Pico-Tesla announced data from an in vivo study completed at the Univ. of
Oklahoma’s Heart Rhythm Institute that suggests extremely low-level electromagnetic fields
(EMFs) can prevent and reverse involuntary remodeling of the heart by terminating and
preventing atrial fibrillation (A-Fib). The principal investigator for the study was Benjamin J.
Scherlag, Ph.D., and Sunny S. Po, M.D., Ph.D. of the Heart Rhythm Institute, University of
Oklahoma Health Sciences Center.
Pico-Tesla’s Magneceutical® Therapy involves the use of an extremely low-level electromagnetic
field (EMF) applied by a specially designed device—the Resonator™, invented by Dr. Jerry I.
Jacobson, along with proprietary therapeutic protocols—intended to improve a number of the
signs and symptoms of major diseases. Pico-Tesla is currently sponsoring clinical trials for
both Parkinson’s disease and type-2 diabetes, and expects to begin a clinical trial for A-Fib
in the fourth quarter of this year.
“We strongly believe that there is a distinct biologic effect utilizing our technology to treat A-Fib,
and we are finalizing details with leading cardiology groups for an exploratory study that includes
men and women with paroxsysmal A-Fib,” said Allen Braswell, CEO of Pico-Tesla.
About EP Lab Digest
EP Lab Digest offers both continuous education and a forum through which electrophysiology
professionals share information on best practices, the latest procedures, and ongoing concerns. Articles
undergo a review process by members of the advisory Editorial Board and by Clinical Editor Bradley
Knight, M.D.
CAUTION: The Resonator™ device is an Investigational Device limited by federal (or United States) law
to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical® Therapy generally
available outside of Investigational Review Board (IRB)-approved clinical studies.
|
